Quantcast

Latest Centocor Stories

2014-09-30 08:32:38

Acquisition Strengthens Existing Pipeline in Viral Diseases NEW BRUNSWICK, N.J., Sept. 30, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. The acquisition will include Alios BioPharma's portfolio of potential therapeutics for viral infections including...

2014-09-03 08:33:24

NEW BRUNSWICK, N.J., Sept. 3, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2014 Morgan Stanley Health Care Conference on Wednesday, Sept. 10, at the Grand Hyatt New York. Dominic Caruso, Vice President, Finance & Chief Financial Officer will represent the Company in a session scheduled at 9:45 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at...

2014-08-14 23:11:39

BioScience Laboratories, Inc. can now screen psoriasis drug formulations in their Skin Technology Center utilizing an in-vitro human psoriasis tissue model. Bozeman, MT (PRWEB) August 14, 2014 Psoriasis is an immune-mediated disease that results in deep skin cells rising rapidly to the surface in just days, rather than the normal month. Extra skin cells build up and form thick, silvery scales and dry red patches that often present on the elbows, knees, scalp, back, face, palms and feet of...

2014-08-05 08:35:59

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growthhttp://www.reportbuyer.com/pharma_healthcare/treatments/systemic_psoriasis_therapeutics_major_developed_markets_2020_continued_uptake_biologics_novel_pipeline_drugs_drive_growth.htmlSystemic Psoriasis Therapeutics in Major Developed Markets to 2020 -...

2014-07-24 16:24:29

Emerging Therapies, Especially IL-17 Inhibitors, Have Potential Relative to Current Therapies in Improving Psoriatic Plaques, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, according to surveyed U.S. and EU5 dermatologists, short-term and long-term effects on psoriatic plaque clearance are two of the attributes that most strongly influence their prescribing decisions in moderate to severe psoriasis....

2014-07-21 16:26:51

NEW BRUNSWICK, N.J., July 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the company's common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for...

2014-06-19 08:28:47

-- Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer's, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections -- NEW BRUNSWICK, N.J., June 19, 2014 /PRNewswire/ -- Johnson & Johnson Innovation, LLC today announced 12 new alliances with life science companies and research institutions around the globe to explore early-stage innovation in a broad range of therapeutic areas and across...

2014-06-14 23:01:22

The Firm is representing hundreds of women who have filed vaginal mesh lawsuits against Johnson & Johnson’s Ethicon unit in state and federal courts. New York, New York (PRWEB) June 14, 2014 As the litigation surrounding vaginal mesh complications (http://www.transvaginalmeshlawsuithelp.com/transvaginal-mesh-complications/) allegedly caused by devices used to treat pelvic organ prolapse and stress urinary incontinence continues to grow, Bernstein Liebhard LLP notes that the Illinois...

2014-05-22 08:30:31

- More than 30 major product filings planned through 2016 NEW BRUNSWICK, N.J., May 22, 2014 /PRNewswire/ -- At a meeting today with members of the investment community, senior leaders from the Medical Devices and Diagnostics (MD&D) segment of Johnson & Johnson (NYSE: JNJ) will outline plans to improve patient outcomes and expand their market leadership through innovative products, new business models and a significant focus on fast-growing emerging markets. Creating Value through...

2014-05-09 16:24:31

Study Evaluating Novel Investigational IL-17 Receptor Antibody Meets All Primary and Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, May 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1(TM) study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment in development that binds to the...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related